OncoMatch/Clinical Trials/NCT06677879
A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
Is NCT06677879 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
The goal of this study is to investigate the differences in toxicity and efficacy between proton and photon hypofractionated radiotherapy following lumpectomy or mastectomy for breast cancer. The main questions it aims to answer are: 1. What is the difference in the incidence of radiation-related grade 2 or higher adverse events within two years following proton versus photon therapy after breast-conserving surgery? 2. What is the difference in the incidence of radiation-related grade 2 or higher adverse events within two years following proton versus photon therapy after mastectomy?
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage PT1-3 N1-3, YPT1-3 N0-3 (pathologic (p/yp))
Excluded: Stage N3C
Postoperative pathology staged as pT1-3 N1-3, excluding N3c. Postoperative stage of ypT1-3 N0-3, excluding N3c. Tumor staging: Patients presenting with T4, N0, or N3c disease [excluded].
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: neoadjuvant chemotherapy — neoadjuvant
Patients who have received neoadjuvant chemotherapy
Must have received: endocrine therapy — neoadjuvant
Patients who have received neoadjuvant...endocrine...therapy
Must have received: targeted therapy — neoadjuvant
Patients who have received neoadjuvant...targeted therapy
Cannot have received: radiation therapy
History of prior radiotherapy to the ipsilateral chest or breast
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify